Exploratory study on pharmacokinetics and optimum dosing regimen of cefmetazole, flomoxef and ceftolozane-tazobactam as prophylaxis for surgical site infection by ESBL-producing Escherichia coli after lower gastrointestinal surgery

Ohge Hiroki0 sites29 target enrollmentDecember 18, 2019

Conditionslower gastrointestinal disease with surgical indication (regardless of benign or malignant)lower gastrointestinal infection, intra-abdominal infection

Overview

Phase: 未知
Intervention: Not specified
Conditions: lower gastrointestinal disease with surgical indication (regardless of benign or malignant)
Sponsor: Ohge Hiroki
Enrollment: 29
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study has provided a foothold for clarifying the mechanism of postoperative infection caused by ESBL-producing E. coli, and has also clarified the tissue migration and concentration maintenance of each antimicrobial agent, such as the tendency of CTLZ and TAZ to maintain high concentrations in the peritoneum. We believe that the results of this study will contribute to the prevention of postoperative complications by selecting the optimal antimicrobial agent according to surgical invasion and time requ

Registry

who.int

Start Date

December 18, 2019

End Date

April 30, 2021

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Ohge Hiroki

Eligibility Criteria

Inclusion Criteria

•1 Patients scheduled for elective lower gastrointestinal surgery (regardless of open surgery or laparoscopic surgery)
•gastrointestinal surgery (limited to open surgery cases)
•2 Inpatients over 20 years old (include 20 years old) who agree to participate in this study, regardless of gender
•3 Patients who can give written informed consent to participate in this study

Exclusion Criteria

•1 Patients with a history of allergies to Cefmetazole, Flomoxef, Ceftolozane/Tazobactam or Metronidazole
•2 Patients with a history of allergies to cephems
•3 Combined use of
•4 Patients who are pregnant or nursing
•5 Patients with organic diseases in the brain and spinal cord
•6 Patients with renal dysfunction who have creatinine clearance less than 50 ml / min estimated by Cockloft\-Gault equation
•7 Patients judged inappropriate for this study by the researcher